Atrogi AB, a clinical stage biotech company pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health, today announces that the first subjects have been dosed in a ...

Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...

Rendering a drug effective or ineffective in a flash at the appropriate location—this is the focus of research in ...